Tags

Type your tag names separated by a space and hit enter

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
Prim Care Diabetes. 2014 Jul; 8(2):111-7.PC

Abstract

AIMS

Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens.

METHODS

A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30.

RESULTS

1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001).

CONCLUSIONS

24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30.

Authors+Show Affiliations

Centro de Atención Integral en Diabetes, Endocrinología y Metabolismo, Chacabuco, Province of Buenos Aires, Argentina.Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.Medicine Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.Department of Endocrinology, First Moscow State Medical University, Moscow, Russia.Novo Nordisk Region International Operations A/S, Zurich, Switzerland. Electronic address: jwch@novonordisk.com.Endocrine Service at the University Hospital "Dr José E González" School of Medicine UANL, Monterrey, Mexico.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23953707

Citation

Dieuzeide, Guillermo, et al. "Safety and Effectiveness of Biphasic Insulin Aspart 30 in People With Type 2 Diabetes Switching From Basal-bolus Insulin Regimens in the A1chieve Study." Primary Care Diabetes, vol. 8, no. 2, 2014, pp. 111-7.
Dieuzeide G, Chuang LM, Almaghamsi A, et al. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Prim Care Diabetes. 2014;8(2):111-7.
Dieuzeide, G., Chuang, L. M., Almaghamsi, A., Zilov, A., Chen, J. W., & Lavalle-González, F. J. (2014). Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Primary Care Diabetes, 8(2), 111-7. https://doi.org/10.1016/j.pcd.2013.07.005
Dieuzeide G, et al. Safety and Effectiveness of Biphasic Insulin Aspart 30 in People With Type 2 Diabetes Switching From Basal-bolus Insulin Regimens in the A1chieve Study. Prim Care Diabetes. 2014;8(2):111-7. PubMed PMID: 23953707.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. AU - Dieuzeide,Guillermo, AU - Chuang,Lee-Ming, AU - Almaghamsi,Abdulrahman, AU - Zilov,Alexey, AU - Chen,Jian-Wen, AU - Lavalle-González,Fernando J, Y1 - 2013/08/14/ PY - 2013/04/29/received PY - 2013/07/03/revised PY - 2013/07/19/accepted PY - 2013/8/20/entrez PY - 2013/8/21/pubmed PY - 2015/1/21/medline KW - A(1)chieve KW - Basal-bolus insulin regimen KW - Biphasic insulin aspart KW - Type 2 diabetes SP - 111 EP - 7 JF - Primary care diabetes JO - Prim Care Diabetes VL - 8 IS - 2 N2 - AIMS: Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens. METHODS: A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30. RESULTS: 1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001). CONCLUSIONS: 24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30. SN - 1878-0210 UR - https://www.unboundmedicine.com/medline/citation/23953707/Safety_and_effectiveness_of_biphasic_insulin_aspart_30_in_people_with_type_2_diabetes_switching_from_basal_bolus_insulin_regimens_in_the_A1chieve_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1751-9918(13)00085-5 DB - PRIME DP - Unbound Medicine ER -